000134825 001__ 134825
000134825 005__ 20240229111723.0
000134825 0247_ $$2doi$$a10.1007/s10557-018-6783-0
000134825 0247_ $$2pmid$$apmid:29679302
000134825 0247_ $$2ISSN$$a0920-3206
000134825 0247_ $$2ISSN$$a1573-7241
000134825 0247_ $$2altmetric$$aaltmetric:41853768
000134825 037__ $$aDKFZ-2018-00615
000134825 041__ $$aeng
000134825 082__ $$a610
000134825 1001_ $$0P:(DE-He78)747b703d2a306c4276ea9e4ee9b5fe44$$aHoppe, Liesa$$b0$$eFirst author$$udkfz
000134825 245__ $$aAssociation of Abnormal Serum Potassium Levels with Arrhythmias and Cardiovascular Mortality: a Systematic Review and Meta-Analysis of Observational Studies.
000134825 260__ $$aDordrecht [u.a.]$$bSpringer Science + Business Media B.V$$c2018
000134825 3367_ $$2DRIVER$$aarticle
000134825 3367_ $$2DataCite$$aOutput Types/Journal article
000134825 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1673443058_10980$$xReview Article
000134825 3367_ $$2BibTeX$$aARTICLE
000134825 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000134825 3367_ $$00$$2EndNote$$aJournal Article
000134825 520__ $$aTo provide the first systematic review and meta-analysis of observational studies on the association of abnormal serum potassium and cardiovascular outcomes.Medline and ISI Web of Knowledge were systematically searched from inception until November 24, 2017. Data synthesis of relevant studies was performed using random effects model meta-analyses.Meta-analyses included 310,825 participants from 24 studies. In the older general population, low serum potassium was associated with a 1.6-fold increased risk of supraventricular arrhythmias (risk ratio [95% confidence interval] 1.62 [1.02-2.55]). Contrarily, high serum potassium was associated with increased cardiovascular mortality (CVM) (1.38 [1.14-1.66]). In patients with acute myocardial infarction, the risk of ventricular arrhythmias was increased for high serum potassium (2.33 [1.60-3.38]). A U-shaped association was observed with a composite cardiovascular outcome in hypertensive patients (2.6-fold increased risk with hypokalemia and 1.7-fold increased risk with hyperkalemia), with CVM in dialysis patients (1.1-fold increased risk with hypokalemia and 1.4-fold increased risk with hyperkalemia) and with CVM in heart failure patients (albeit not statistically significant). Further, only hyperkalemia was associated with an increased risk of a composite cardiovascular outcome in both dialysis (1.12 [1.03-1.23]) and chronic kidney disease (1.34 [1.06-1.71]) patients.Controlled clinical trials are needed to determine which populations may profit from more frequent potassium-monitoring and subsequent interventions, e.g., change or withdrawal of potassium-influencing drugs, in order to restore normal values and prevent cardiovascular outcomes.Registration in PROSPERO (Centre for Reviews and Dissemination University of York, York, UK): CRD42016048897 ( https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=48897 ).
000134825 536__ $$0G:(DE-HGF)POF3-323$$a323 - Metabolic Dysfunction as Risk Factor (POF3-323)$$cPOF3-323$$fPOF III$$x0
000134825 588__ $$aDataset connected to CrossRef, PubMed,
000134825 7001_ $$0P:(DE-He78)358cd16fe1dd16be6e4eaf0e76e5ad57$$aMuhlack, Dana Clarissa$$b1$$udkfz
000134825 7001_ $$aKoenig, Wolfgang$$b2
000134825 7001_ $$0P:(DE-He78)7d7ee36ed0313bbc4c91bc3df5950107$$aCarr, Prudence$$b3$$udkfz
000134825 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b4$$udkfz
000134825 7001_ $$0P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aSchöttker, Ben$$b5$$eLast author$$udkfz
000134825 773__ $$0PERI:(DE-600)2003553-6$$a10.1007/s10557-018-6783-0$$gVol. 32, no. 2, p. 197 - 212$$n2$$p197 - 212$$tCardiovascular drugs and therapy$$v32$$x1573-7241$$y2018
000134825 909CO $$ooai:inrepo02.dkfz.de:134825$$pVDB
000134825 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)747b703d2a306c4276ea9e4ee9b5fe44$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000134825 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)358cd16fe1dd16be6e4eaf0e76e5ad57$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000134825 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7d7ee36ed0313bbc4c91bc3df5950107$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000134825 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000134825 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000134825 9131_ $$0G:(DE-HGF)POF3-323$$1G:(DE-HGF)POF3-320$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lHerz-Kreislauf-Stoffwechselerkrankungen$$vMetabolic Dysfunction as Risk Factor$$x0
000134825 9141_ $$y2018
000134825 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000134825 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000134825 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000134825 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000134825 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCARDIOVASC DRUG THER : 2015
000134825 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000134825 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000134825 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000134825 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000134825 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000134825 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000134825 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000134825 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000134825 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000134825 9201_ $$0I:(DE-He78)G110-20160331$$kG110$$lPräventive Onkologie$$x1
000134825 980__ $$ajournal
000134825 980__ $$aVDB
000134825 980__ $$aI:(DE-He78)C070-20160331
000134825 980__ $$aI:(DE-He78)G110-20160331
000134825 980__ $$aUNRESTRICTED